Back to Atlas
CTransientStandard research/education caution
CMP-0290
Discontinued investigational
Brilanestrant / GDC-0810
Endocrine / SERD
ER-positive breast cancer endocrine research positioning
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Oral SERD
- Primary mechanism
- Estrogen receptor antagonist/degrader
- Primary market use
- Oncology / endocrine
Pharmacology
- Molecular weight (Da)
- 544.6
- Oral bioavailability
- Oral investigational
- Half-life
- ~8-10 h; not consistently disclosed
- Route tags
- Oral
- Evidence level
- Clinical
- Clinical status
- Discontinued investigational
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Older oral SERD; discontinued but relevant to class landscape